WASHINGTON--(BUSINESS WIRE)--Abiomed Inc. (NASDAQ: ABMD), today announced its schedule of events at the Cardiovascular Research Foundation’s (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting, scheduled from Saturday, October 20, to Thursday, October 25, in Washington, D.C. Abiomed will be announcing clinical data on its breakthrough Impella 2.5 percutaneous Ventricular Assist Device (VAD), including results from a multi-center feasibility study of adult patients that had high-risk Percutaneous Coronary Interventions (PCI). The Impella 2.5 is the world’s smallest VAD which provides patients with up to 2.5 liters of blood flow per minute and has been used under CE Mark approval in Europe to treat conditions such as acute myocardial infarction (heart attack), cardiogenic shock, and low output syndrome. Due to a rise in conditions such as triple vessel disease in patients with poor cardiac function, which is caused by coronary vessel blocks in three vessels of the heart, the Impella 2.5 provides a new treatment option that aims to improve patient outcomes. Additionally, at Booth 6121, Abiomed will showcase its complete portfolio of heart recovery products across the continuum of patient care from the cath lab, to the intensive care unit, to the surgery suite.
